January 25, 2017 | EphMRA, Patient research, Rachel Howard, emerging markets
We are delighted to be attending and presenting a paper at the EphMRA one day meeting on Tuesday 21st February, in London
Emerging markets expert Rachel Howard will be presenting the paper ‘Patient Willingness to Pay in the Real World’ from 14.35 – 15.05 pm.Â
http://www.researchpartnership.com/news/2017/01/ephmra-one-day-meeting/
This content was provided by Inizio
Latest Content from Inizio
Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30…
Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs – it was also a showcase for how technology is redefining congress engagement. Supporting…
Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke. This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic…
At Inizio, we provide tailored, innovative solutions to help health and life sciences companies with their clinical development and commercialization journeys, maximizing patient access. Our experts guide you through each…
Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and…
This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across…
Authored by: Ellie Forde and Mark Braund, Directors
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.
The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address…
The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our…
